

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the following sections, added text is marked with double underlining. e.g. added text, and deleted text is marked by a single strikethrough, e.g. ~~deleted text~~.

IN THE SPECIFICATION

The paragraph beginning at page 1, line 3 and ending at page 1, line 6 has been amended as follows:

This application is a continuation of U.S. Non-Provisional Application 09/611,419 filed July 6, 2000 which is based on U.S. Provisional Applications Nos. 60/133,866, 60/133,868, 60/133,869, 60/133,865, 60/133,873, and 60/133,867, all filed May 12, 1999, and U.S. Provisional Application No. 60/146,192, filed July 29, 1999, and U.S. Patent Application No. 08/123,975, filed September 21, 1993, all of which are incorporated herein by reference in their entirety.

NO  
COPYING

The paragraph beginning at page 21, line 20 and ending at page 21, line 29 has been amended as follows:

Analysis of CD spectra of both soluble and resolubilized product revealed the presence of significant  $\beta$ -sheet which is in agreement with that predicted for rBoNTF(H<sub>C</sub>) using an artificial neural network (Lebeda, F.J., et al., (1997), "Predicting Differential Antigen-Antibody Contact Regions Based on Solvent Accessibility," *J. Protein Chem.*, 16:607-618), and that determined by crystal structure of BoNT serotype A (Lacy, D.B., et al., (1998), "Crystal Structure of Botulinum Neurotoxin Type A and